#United States #San Diego #Immunotherapy #Oncolytics Biotech #pelareorep

Oncolytics Biotech® Prepares for Upcoming Annual General Meeting and Financial Results

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a prominent company in the field of clinical-stage immunotherapy, has officially announced the details of its upcoming Annual General Meeting (AGM) and the financial results for the second quarter of 2025. The meeting is set for August 8, 2025, at 10:00 AM Eastern Time and will be conducted entirely online. This virtual format aims to facilitate broader participation from shareholders.

After the formal proceedings of the AGM, the Chief Executive Officer, Jared Kelly, will deliver a corporate update, reflecting on strategic milestones set for the remainder of the year. This is particularly exciting for stakeholders as it will provide insights into the company’s future directions and advancements. Additionally, the financial results for the second quarter will be released prior to the market opening on the same day, providing a comprehensive financial overview for investors.

For those interested in attending, guests can access the meeting by visiting the webcast site. Participants will be directed to click on the "I am a Guest" button and complete a brief registration form. If required, the password to join as a guest is onc2025, which is case-sensitive.

The detailed guidelines for shareholders wishing to vote by proxy and attend the meeting are outlined in the Company’s most recent Management Information Circular dated June 18, 2025. This circular is accessible on the investor relations section of Oncolytics’ website and is available in securities filings in both Canada and the United States.

Registered shareholders who have not appointed a proxyholder, as well as duly appointed proxyholders (including those who appoint themselves), will have the capability to attend the meeting and vote in real-time as long as they have internet connectivity. However, non-registered shareholders without proper appointment as proxyholders may only attend as guests, thereby forfeiting their voting rights.

About Oncolytics Biotech Inc.

Oncolytics Biotech is at the forefront of clinical-stage biotechnology, with its primary focus on developing pelareorep, a cutting-edge immunotherapeutic agent administered intravenously. Pelareorep has exhibited promising outcomes in two randomized Phase 2 clinical trials for metastatic breast cancer, as well as in early-phase studies envisaging its utility in pancreatic and colorectal cancers. Its mechanism revolves around transforming immunologically “cold” tumors into “hot” tumors by stimulating innate and adaptive immune responses.

The company’s current initiatives are advancing pelareorep alongside chemotherapy and checkpoint inhibitors for metastatic breast and pancreatic cancers, both of which have gained Fast Track designation from the FDA. To amplify its development endeavors and maximize its commercial potential, Oncolytics is actively seeking strategic partnerships.

For further information, interested parties can visit Oncolytics Biotech’s official website or follow the company on social media platforms including LinkedIn and X @oncolytics. This engagement is vital for those tracking the developments within this promising field of immunotherapy and oncology.

In summary, the upcoming Annual General Meeting constitutes a significant event for Oncolytics Biotech, providing shareholders with the latest company insights while presenting an opportunity for ongoing engagement in their innovative cancer therapies.